Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

593
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
593
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

217
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
217
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

235
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
235
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of Esophageal and Gastric Varices in Patients With Cirrhosis for Clinical Trials: A Centralized Blinded Evaluation System.

Gastro hep advances·2026
Same author

Breath-Based Diagnostics in Liver Diseases: Dynamic Assessment of Hepatic Metabolic Reserve and Liver Fibrosis.

Gastro hep advances·2026
Same author

Therapeutic development in MASH: From accelerated approval to cirrhosis trial innovation.

Med (New York, N.Y.)·2026
Same author

Propelling MASLD trials into the era of non-invasive tests.

The lancet. Gastroenterology & hepatology·2026
Same author

Clinical Features and Outcomes of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease With Increased Alcohol Intake.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis.

Clinics in liver disease·2026
Same journal

Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence.

Obesity (Silver Spring, Md.)·2026
Same journal

Appetite Suppression by GLP-1 Receptor Agonists: Role of Delayed Gastric Emptying.

Obesity (Silver Spring, Md.)·2026
Same journal

DXA-Measured Visceral Adipose Tissue and Accelerated Biological Aging in Middle-Aged Adults.

Obesity (Silver Spring, Md.)·2026
Same journal

Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery.

Obesity (Silver Spring, Md.)·2026
Same journal

Prospective Association Between Weight Variability and Subsequent Long-Term Weight Loss in the CALERIE Study.

Obesity (Silver Spring, Md.)·2026
Same journal

Dietary Protein Reduction During Isocaloric Conditions Reduces Body Weight in Men With Overweight or Obesity.

Obesity (Silver Spring, Md.)·2026
See all related articles

Related Experiment Video

Updated: Jan 13, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

901

Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week

Harold E Bays1, Phillip Toth2, Naim Alkhouri3

  • 1Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville, Kentucky, USA.

Obesity (Silver Spring, Md.)
|January 9, 2026
PubMed
Summary
This summary is machine-generated.

VK2735, a novel GLP-1/GIP receptor agonist, demonstrated significant weight loss in adults with overweight or obesity. Doses ranged from 9.1% to 14.7% reduction over 13 weeks, with manageable gastrointestinal side effects.

Keywords:
GLP‐1antiobesityobesity treatmentweight lossweight management

More Related Videos

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.6K

Related Experiment Videos

Last Updated: Jan 13, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

901
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.5K
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

1.6K

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • The VENTURE study (NCT06068946) investigated VK2735, a novel dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) receptor agonist.
  • Obesity and overweight are significant global health concerns requiring effective therapeutic interventions.

Purpose of the Study:

  • To determine effective doses of VK2735 for weight loss in adults with obesity or overweight over a 13-week treatment period.
  • To evaluate the efficacy and safety profile of weekly subcutaneous VK2735.

Main Methods:

  • A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study.
  • Inclusion criteria: adults with obesity or overweight and at least one weight-related comorbidity (excluding diabetes mellitus).
  • Primary endpoint: percent change from baseline in body weight at Week 13.

Main Results:

  • Mean weight reduction with VK2735 ranged from 9.1% (2.5 mg) to 14.7% (15 mg), compared to 1.7% for placebo.
  • 93% of participants on active treatment achieved ≥5% weight loss versus 12% on placebo.
  • Gastrointestinal adverse events were common but decreased in frequency with continued use.

Conclusions:

  • All tested subcutaneous doses of VK2735 significantly reduced body weight.
  • VK2735 demonstrated a favorable efficacy profile for weight management.
  • The drug's primary adverse events were gastrointestinal, with improved tolerability over time.